Last updated: 2026-11-13 13:10:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Boston Scientific Corp. (BSX) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $44.27, with a market capitalization of $64.07B and a P/E ratio of 18.29. Over the past 52 weeks, its price has ranged from $39.57 to $105.65. This page covers its latest market performance, valuation, price trends and company information.
$64.07B | |
$44.49 | |
$45.00 | |
$44.18 | |
$44.20 | |
3.59K | |
19.53M | |
18.29 | |
$105.65 | |
$39.57 | |
-- | |
12-31 |
Boston Scientific Corp. (BSX) is trading at $44.27 in pre-market trading as of 2026-11-13 13:08:00, up 0.15% ($0.07) from the previous close of $44.20
Pre-market trading shows how investors are pricing BSX before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Boston Scientific Corp. (BSX) moved from $44.64 to $44.27, representing a decline of 0.84% ($0.37).
The stock traded between $42.69 and $46.85 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 13.49 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 7.1%
BSX is currently trading at $44.27, placing it 7.1% of the way from its 52-week low of $39.57 to its 52-week high of $105.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 59,000 |
| CEO | Michael F. Mahoney |
| Founded | 1979 |
| Exchange | NYSE |
| Company Website |
Latest news related to Boston Scientific Corp. and BSX stock.
Boston Scientific's WATCHMAN left atrial appendage closure device continues to face declining demand despite positive clinical trial results and expansion efforts. The company expects low-single-digit sequential sales declines in Q3 2026 and assumes no market improvement in 2027, while competitors like Abbott and Edwards Lifesciences show stronger momentum in electrophysiology and structural heart segments.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Abbott (ABT) announced FDA and CE Mark approvals for its UltiSynq defibrillation lead, which delivers both pacing and defibrillation therapy. The ASCEND CSP IDE trial demonstrated a 98.5% successful implantation rate, 97.5% complication-free rate, and 100% successful defibrillation in 120 tested patients. The device received FDA breakthrough designation. Competitors Medtronic and Boston Scientific also reported positive clinical results for their respective cardiac devices.
Eligible investors can buy real shares of Boston Scientific Corp. (BSX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as Boston Scientific Corp.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to BSX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between BSX shares and USD.
BSX Shares to USD
1.00 BSX shares = 44.267 USD
Calculations are estimates based on the latest available price and are for reference only.
